Jalupro Young Eye is a specialized eye contour treatment designed to reduce signs of aging and fatigue effectively. With its unique formulation of hyaluronic acid and amino acids, this targeted treatment hydrates and firms the delicate eye area. Whether used to address dark circles, puffiness, or crow’s feet, Jalupro Young Eye offers comprehensive rejuvenation for brighter and more youthful-looking eyes. Each application provides long-lasting results, restoring under-eye clarity and vitality. With regular use, individuals can enjoy visibly rejuvenated and refreshed eyes, enhancing their natural beauty and confidence.
Jalupro Young Eye 1m
Jalupro Young Eye is a highly effective dermal filler designed for under-eye rejuvenation. Formulated by Professional Derma SA, it combines two types of hyaluronic acid, three peptides, and seven amino acids to comprehensively treat the eye area with advanced biotechnology.
€88,80
Brand
Jalupro
Specification
The pack consists of:
1 x 1 ml syringe prefilled syringe
Composition of the product:
Sodium Hyaluronate
Glycine
Peptides: L-proline, L-leucine, L-lysine HCL, L-alanine, L-valine, L-arginine HCL
Amino acids: Acetyl Decapeptide 3, Oligopeptide 24, Acetyl Tetrapeptide 5, Buffer Phosphate
Water for injection
Benefits of Jalupro Young Eye:
Strengthens the connective tissue around the eyes
Treats common signs of skin aging
Can be used as a standalone treatment or in conjunction with other therapies
Results and indication:
Jalupro Young Eye should be injected into the deep layer of the dermis. It is recommended to get 4-6 applications with one a week. The manufacturer recommends using 30G needles. The product can be used in combination with peels and laser treatments.
THE ORIGIN OF THIS PRODUCT IS FROM THEÂ EUROPEAN COMMUNITY (EC)
Discount
5 packs: Save 3% = € 71,78 per pack
10 packs: Save 5% = € 70,30 per pack
20 packs: Save 8% = € 68,08 per pack
30 packs: Save 10% = € 66,60 per pack
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.